DT was talking about the potential sales of Bisantrene when it is both cardio protective as well as cancer killing based on the Triangle Insights (ASX Announcement: 14 April 2023 report. Also have a look at the May 2024 presentation page 16. It says Note: All forecasted revenues reflect a 50% reduction to the physician-stated adoption rate. Then have a look at the right hand side. It is US$3.5 to US$7.00 range as annual income worldwide which if after the 50% reduction. Buyout is 2.5 to 5 times annual income. Now calculate a bit and you will understand why DT is hesitant about the numbers as it is so obscene. Also keep in mind this totally excludes the FTO. Now let your head spinning a bit, be super conservative and you will have any idea hwo it would impact the current share price.
RAC media coverage, page-2163
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
0.000(0.00%) |
Mkt cap ! $247.1M | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.45 | $1.35 | $254.2K | 185.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 212 | $1.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 5981 | 3 |
View Market Depth
| Last trade - 16.10pm 18/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |